GlassScriptPhysician profile
Teresa May Merced
NPI 1083645550
$1,091.57
in general payments reported to CMS, 2019-2025
15 companies · $445 in 2025
The $445 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $156 · 2021: $75.35 · 2022: $134 · 2023: $132 · 2024: $149 · 2025: $445.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $726.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $725.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Paratek Pharmaceuticals, INC. | $277.51 | 2020-2025 | Nuzyra |
| Baxter Healthcare | $195.09 | 2022-2025 | Hillrom - Vest System Model 105 Home Care |
| Electromed, INC. | $133.91 | 2025 | Smartvest |
| Grifols USA, LLC | $80.69 | 2020-2023 | Prolastin-C Liquid |
| Astrazeneca Pharmaceuticals LP | $64.73 | 2022-2023 | Farxiga, Fasenra |
| United Therapeutics Corporation | $56.56 | 2021-2024 | Tyvaso |
| Actelion Pharmaceuticals US, INC. | $52.97 | 2022-2025 | Uptravi, Opsumit |
| Amgen INC. | $39.62 | 2024 | Tepezza |
| Alexion Pharmaceuticals, INC. | $35.49 | 2021 | |
| Pfizer INC. | $35.32 | 2021-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.57 | 2023 | Synjardy, Jardiance, Tradjenta |
| Tanabe Pharma America, INC. | $28.18 | 2022 | |
| Shionogi INC | $27.58 | 2023 | Fetroja |
| Abbott Laboratories | $18.31 | 2024 | Eterna |
| Viiv Healthcare Company | $16.04 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Teresa Merced listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.